Bradley Cole most recently served as Executive Advisor at Exact Sciences and previously, as General Manager, Precision Oncology at Exact Sciences from November 2019 until April 2020. From 2004 to 2019, he held various roles at Genomic Health including Chief Financial Officer, Chief Operating Officer, and Secretary; ultimately playing a key role in the acquisition of Genomic Health by Exact Sciences in mid 2019.
From 1997 to 2004, Brad served in various Vice President roles at Guidant Corporation, in both finance and general management. From July 1994 through 1997 he served as Chief Financial Officer of Endovascular Technologies, which was acquired by Guidant Corporation. Previously, Brad served as Chief Financial Officer of Applied Biosystems Incorporated, a life sciences systems company from 1988 through 1994.
Brad currently serves on the boards of directors of Castle Biosciences, a skin cancer diagnostics company; and Kiniksa, a biopharmaceutical company focusing on therapeutics for underserved conditions; and as Vice Chairman of the Board of Trustees of Biola University. He holds a Bachelor of Science degree in Business from Biola University and an M.B.A. from San Jose State University.